The Sensitivity of Arterial Spin-Labeling Imaging for Detection of Head and Neck Paragangliomas

REFERENCES

1. 1.↵
   1. Lin EP,
   2. Chin BB,
   3. Fishbein L, et al

   . Head and neck paragangliomas: an update on the molecular classification, state-of-the-art imaging, and management recommendations. Radiol Imaging Cancer 2022;4:e210088 doi:10.1148/rycan.210088 pmid:35549357

   CrossRefPubMed
2. 2.↵
   1. Pellitteri PK,
   2. Rinaldo A,
   3. Myssiorek D, et al

   . Paragangliomas of the head and neck. Oral Oncol 2004;40:563–75 doi:10.1016/j.oraloncology.2003.09.004 pmid:15063383

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Chang CA,
   2. Pattison DA,
   3. Tothill RW, et al

   . (68)Ga-DOTATATE and (18)F-FDG PET/CT in paraganglioma and pheochromocytoma: utility, patterns and heterogeneity. Cancer Imaging 2016;16:22 doi:10.1186/s40644-016-0084-2 pmid:27535829

   CrossRefPubMed
4. 4.↵
   1. Rini JN,
   2. Keir G,
   3. Caravella C, et al

   . Somatostatin receptor-PET/CT/MRI of head and neck neuroendocrine tumors. AJNR Am J Neuroradiol 2023;44:959–66 doi:10.3174/ajnr.A7934 pmid:37442593

   Abstract/FREE Full Text
5. 5.↵
   1. Amar L,
   2. Pacak K,
   3. Steichen O, et al

   . International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. Nat Rev Endocrinol 2021;17:435–44 doi:10.1038/s41574-021-00492-3 pmid:34021277

   CrossRefPubMed
6. 6.↵
   1. Geerts B,
   2. Leclercq D,
   3. Tezenas Du Montcel S, et al

   . Characterization of skull base lesions using pseudo-continuous arterial spin labeling. Clin Neuroradiol 2019;29:75–86 doi:10.1007/s00062-017-0623-7 pmid:28894884

   CrossRefPubMed
7. 7.↵
   1. Neves F,
   2. Huwart L,
   3. Jourdan G, et al

   . Head and neck paragangliomas: value of contrast-enhanced 3D MR angiography. AJNR Am J Neuroradiol 2008;29:883–89 doi:10.3174/ajnr.A0948 pmid:18339724

   Abstract/FREE Full Text
8. 8.↵
   1. Ota Y,
   2. Liao E,
   3. Capizzano AA, et al

   . Diagnostic role of diffusion-weighted and dynamic contrast-enhanced perfusion MR imaging in paragangliomas and schwannomas in the head and neck. AJNR Am J Neuroradiol 2021;42:1839–46 doi:10.3174/ajnr.A7266 pmid:34446460

   Abstract/FREE Full Text
9. 9.↵
   1. Wong EC

   . An introduction to ASL labeling techniques. J Magn Reson Imaging 2014;40:1–10 doi:10.1002/jmri.24565 pmid:24424918

   CrossRefPubMed
10. 10.↵
    1. Haller S,
    2. Zaharchuk G,
    3. Thomas DL, et al

    . Arterial spin-labeling perfusion of the brain: emerging clinical applications. Radiology 2016;281:337–56 doi:10.1148/radiol.2016150789 pmid:27755938

    CrossRefPubMed
11. 11.↵
    1. Puig O,
    2. Henriksen OM,
    3. Vestergaard MB, et al

    . Comparison of simultaneous arterial spin labeling MRI and (15)O-H(2)O PET measurements of regional cerebral blood flow in rest and altered perfusion states. J Cereb Blood Flow Metab 2020;40:1621–33 doi:10.1177/0271678X19874643 pmid:31500521

    CrossRefPubMed
12. 12.↵
    1. Jarnum H,
    2. Steffensen EG,
    3. Knutsson L, et al

    . Perfusion MRI of brain tumours: a comparative study of pseudo-continuous arterial spin labelling and dynamic susceptibility contrast imaging. Neuroradiology 2010;52:307–17 doi:10.1007/s00234-009-0616-6 pmid:19841916

    CrossRefPubMedWeb of Science
13. 13.↵
    1. McHugh ML

    . Interrater reliability: the kappa statistic. Biochem Med (Zagreb) 2012;22:276–82 doi:10.11613/BM.2012.031

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Richter S,
    2. Qiu B,
    3. Ghering M, et al

    . Head/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine. Endocr Relat Cancer 2022;29:213–24 doi:10.1530/ERC-21-0359 pmid:35171114

    CrossRefPubMed
15. 15.↵
    1. Offergeld C,
    2. Brase C,
    3. Yaremchuk S, et al

    . Head and neck paragangliomas: clinical and molecular genetic classification. Clinics (Sao Paulo) 2012;67(Suppl 1):19–28 doi:10.6061/clinics/2012(sup01)05 pmid:22584701

    CrossRefPubMed
16. 16.↵
    1. Taieb D,
    2. Kaliski A,
    3. Boedeker CC, et al

    . Current approaches and recent developments in the management of head and neck paragangliomas. Endocr Rev 2014;35:795–819 doi:10.1210/er.2014-1026 pmid:25033281

    CrossRefPubMed
17. 17.↵
    1. Graham NJ,
    2. Smith JD,
    3. Else T, et al

    . Paragangliomas of the head and neck: a contemporary review. Endocr Oncol 2022;2:R153–62 doi:10.1530/EO-22-0080 pmid:37435464

    CrossRefPubMed
18. 18.↵
    1. Gaddikeri S,
    2. Hippe DS,
    3. Anzai Y

    . Dynamic contrast-enhanced MRI in the evaluation of carotid space paraganglioma versus schwannoma. J Neuroimaging 2016;26:618–25 doi:10.1111/jon.12351 pmid:27102237

    CrossRefPubMed
19. 19.↵
    1. Gimenez-Roqueplo AP,
    2. Caumont-Prim A,
    3. Houzard C, et al

    . Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL.EVA Investigators. J Clin Endocrinol Metab 2013;98:E162–73 doi:10.1210/jc.2012-2975 pmid:23162105

    CrossRefPubMedWeb of Science